Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland — the organ responsible for T-cell maturation and immune system regulation. The synthetic version is bioidentical to the endogenous peptide.
Tα1 works primarily through dendritic cell activation and T-cell differentiation. It stimulates the maturation of T-cells from progenitor cells in the thymus and enhances the function of both CD4+ helper T-cells and CD8+ cytotoxic T-cells. It also activates natural killer (NK) cells and promotes the production of key cytokines including interleukin-2 (IL-2) and interferon-alpha.
Beyond direct immune activation, Tα1 modulates toll-like receptor (TLR) signaling, which helps the immune system recognize and respond to pathogens more effectively. This dual role — both stimulating and regulating immune responses — makes it particularly interesting for conditions involving immune dysfunction rather than simple immune suppression.
Thymosin Alpha-1 has one of the strongest clinical evidence bases of any peptide, with approved pharmaceutical status in over 35 countries (marketed as Zadaxin).
Hepatitis B: Multiple randomized controlled trials have demonstrated that Tα1 combined with interferon-alpha significantly improves sustained virological response rates in chronic hepatitis B patients compared to interferon alone.
Hepatitis C: Clinical trials have shown improved viral clearance rates when Tα1 is added to standard pegylated interferon/ribavirin therapy, particularly in difficult-to-treat genotypes.
Cancer Immunotherapy: Studies in melanoma, hepatocellular carcinoma, and non-small cell lung cancer have explored Tα1 as an adjunct to chemotherapy and immunotherapy. Results suggest improved immune function markers and quality of life, though large-scale efficacy trials are ongoing.
Vaccine Enhancement: Research indicates Tα1 can improve immune responses to vaccines, particularly in elderly and immunocompromised populations where vaccine efficacy is typically reduced.
Sepsis & Critical Care: Clinical data from ICU settings suggests Tα1 may improve outcomes in severe sepsis by restoring immune function in immunoparalyzed patients.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
Thymosin Alpha-1 is administered exclusively via subcutaneous injection. Reported clinical protocols include the following approaches.
Standard Immune Support: 1.6 mg subcutaneously, twice weekly. This mirrors the dosing used in the Zadaxin clinical trials and is the most commonly cited protocol.
Acute Immune Challenge: Some providers increase frequency to 1.6 mg daily for 1–2 weeks during acute infections, then taper to the standard twice-weekly schedule.
Maintenance / Prevention: 1.6 mg once weekly for ongoing immune optimization, often used in longevity-focused protocols.
Typical Cycle Length: 8–12 weeks on, followed by 4 weeks off. Some providers run longer cycles (up to 6 months) for chronic conditions with periodic lab monitoring.
Thymosin Alpha-1 has an excellent safety profile supported by decades of clinical use across 35+ countries. Commonly reported effects include mild injection site reactions (redness, swelling), occasional fatigue in the first few days as the immune system upregulates, and rare instances of mild flu-like symptoms.
Tα1 is generally considered one of the safest peptides available, which is reflected in its approved pharmaceutical status internationally. However, individuals with autoimmune conditions should use caution, as enhanced immune activation could theoretically exacerbate autoimmune responses. Consultation with a provider experienced in immunomodulation is recommended.
Verified suppliers with third-party testing and COA documentation. Use code POWER where applicable.
Thymosin Alpha-1 is not FDA-approved as a standalone drug in the United States, but it is classified as Category 1 (cleared for compounding by licensed pharmacies). It is approved as a pharmaceutical (Zadaxin) in over 35 countries for hepatitis and immune support.
Despite similar names, these are completely different peptides with different functions. Thymosin Alpha-1 is an immune modulator that enhances T-cell function and pathogen recognition. TB-500 (Thymosin Beta-4) is a tissue repair peptide that promotes wound healing, reduces inflammation, and supports cell migration. They target different systems entirely.
Some integrative medicine providers are exploring Tα1 for post-viral immune dysregulation, including long COVID. The rationale is based on its ability to restore T-cell function and modulate inflammatory cytokines. However, controlled clinical trial data for this specific application is still limited.
Immune function improvements are typically measurable via lab work within 2–4 weeks. Subjective improvements in energy and illness frequency are often reported at 4–8 weeks. Chronic infection protocols may take 3–6 months to show full benefit.
Take our 2-minute quiz to get a personalized peptide recommendation based on your goals, experience level, and health priorities.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. Peptide protocols described on this page reflect reported clinical practices and published research — not recommendations. Individual results may vary. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.